5 completed, 2 terminated, 2 unknown, 1 withdrawn. 10 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Completed 5, Terminated 2, Unknown 2, Withdrawn 1 |
| Phase 2 | 7 | Completed 2, Terminated 2, Unknown 2, Withdrawn 1 |
Follow Soliris: new trials by email Literature Review of Soliris trials Research Report on Soliris
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Eculizumab for Prevention of Antibody-Mediated Rejection in ABO-Incompatible Living Donor Kidney Transplantation Eculizumab - Kidney Transplantation | Phase 1 / Phase 2 | Unknown | Tao Lin | 30 | 2024-07-01 | 2024-06-13 |
| The Use of Eculizumab in HELLP Syndrome Eculizumab - HELLP Syndrome (HELLP), Third Trimester, Complement Abnormality | Phase 1 | Completed | Johns Hopkins University | 3 | 2021-02-23 | 2023-11-14 |
| Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris® BCD-148, Soliris - Healthy Subjects | Phase 1 | Completed | Biocad | 78 | 2018-09-21 | 2020-05-15 |
| Eculizumab Therapy for Subclinical Antibody-mediated Rejection in Kidney Transplantation Eculizumab - Subclinical Acute Antibody-mediated Rejection in Kidney Transplantation | Phase 1 / Phase 2 | Withdrawn | Assistance Publique - Hôpitaux de Paris | 2015-02-01 | 2025-11-20 | |
| An Open Label Study of the Effects of Eculizumab in CD59 Deficiency Eculizumab - Chronic Hemolysis | Phase 1 / Phase 2 | Unknown | Hadassah Medical Organization | 5 | 2012-02-01 | 2012-04-18 |
| Eculizumab Therapy for Chronic Complement-Mediated Injury in Kidney Transplantation eculizumab - Kidney; Complications, Allograft | Phase 1 | Completed | Sanjay Kulkarni | 16 | 2011-03-01 | 2019-08-12 |
| Eculizumab to Prevent Antibody-mediated Rejection in ABO Blood Group Incompatible Living Donor Kidney Transplantation Eculizumab - Kidney Transplant | Phase 1 / Phase 2 | Terminated | Mayo Clinic | 6 | 2010-05-01 | 2015-07-20 |
| Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Crossmatch Deceased Donor Kidney Transplant Eculizumab - Kidney Transplant | Phase 1 / Phase 2 | Terminated | Mayo Clinic | 2 | 2010-03-01 | 2018-01-31 |
| An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica Eculizumab - Neuromyelitis Optica, Devic's Disease | Phase 1 / Phase 2 | Completed | Mayo Clinic | 14 | 2009-04-01 | 2013-11-04 |
| Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Cross Match Living Donor Kidney Transplant Eculizumab - Kidney Transplant | Phase 1 / Phase 2 | Completed | Mark Stegall | 31 | 2008-03-01 | 2018-06-26 |
HELLP Syndrome (1) · Neuromyelitis Optica (1)
Mayo Clinic (3) · Assistance Publique - Hôpitaux de Paris (1) · Biocad (1) · Hadassah Medical Organization (1) · Johns Hopkins University (1) · Mark Stegall (1) · Sanjay Kulkarni (1) · Tao Lin (1)
United States (6) · China (1) · Israel (1) · Russia (1)
Arthur J Vaught (1) · Dror Mevorach, MD (1) · Mark D Stegall (1) · Mark D. Stegall, M.D. (1) · Mark Stegall, MD (1) · Sanjay Kulkarni, MD (1) · Sean J. Pittock, M.D. (1)
PMID 21942930, PMID 23623397, PMID 24990476, PMID 27568864
K12HD085845 (1), UL1TR000135 (1)